Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
Another TKI used in cancer
2022-06-09
Another TKI used in cancer therapy is the Abl inhibitor imatinib mesilate which has also a beneficial effect on glucose homeostasis in diabetic humans [39], [40], [41]. Imatinib has a clear impact on NFκB activation and anti-apoptotic preconditioning of β-cells [39], attenuating islet inflammation [
-
The inhibitory activities of the
2022-06-09
The inhibitory activities of the compounds with the modification of the amino group against human liver FBPase are summarized in . Replacement of the amino group of with hydrophobic substituent such as a methyl group () led to a substantial loss of activity (IC=995nM). Similarly, replacement with ha
-
If the manager channel dominates we expect the increase
2022-06-09
If the manager channel dominates, we expect the increase in debt maturity of treated firms relative to control firms to be more evident in firms with weaker corporate governance where managers are less monitored and have more discretion in changing firm risks. We use the governance index (GINDEX) co
-
LEE011 In the present study VTE
2022-06-09
In the present study, VTE recurrence occurred in a non-cancer patient during edoxaban administration, representing recurrence rates of 1.7% in non-cancer patients and 0.8% in all patients. In a sub-analysis of cancer patients [27] and the main analysis [19] in the HOKUSAI-VTE trial, recurrent VTE oc
-
PKC potentiates insulin release in beta cells however it is
2022-06-09
PKC potentiates insulin release in beta cells; however, it is currently not clear how this is mechanistically accomplished in living Mesoridazine Besylate australia [15]. First, we discuss PKC structure, regulation, and activation in beta cells. Then, we address two fundamental questions: (1) what
-
In Kdm c germline and forebrain conditional knockout mice RN
2022-06-08
In Kdm5c germline and forebrain conditional knockout mice, RNA sequencing showed the upregulation of a large set of genes, suggesting that Kdm5c functions primarily as a transcriptional repressor [,]. While no changes in global H3K4me3 levels were observed in the knockout neurons, there were thousan
-
The therapeutic potential of acetate has been advocated
2022-06-08
The therapeutic potential of acetate has been advocated by research on neurodegenerative disorders such as Canavan's disease (Arun et al., 2010, Mathew et al., 2005), where oral acetate improved motor function in a genetic model of the disorder, and in studies of behavioural phenotypes associated wi
-
br Acknowledgments This research was funded
2022-06-08
Acknowledgments This research was funded by generous grants from the Singapore National Medical Research Council (NMRC CBRG grant NMRC/CBRG12Nov114 (BD)). WJC is supported by NMRC Clinician Scientist Investigator award and partly supported by a Singapore Cancer Syndicate Grant, the National Resea
-
The majority of HCV unaware individuals
2022-06-08
The majority of HCV-unaware individuals, for which HCV RNA was obtainable, had active HCV infection and overall almost one-fifth of them had advanced liver disease according to the FIB-4 score; these persons can be classified as having a late HCV diagnosis and are in immediate need of HCV treatment
-
br Author Contributions br Acknowledgments We thank
2022-06-08
Author Contributions Acknowledgments We thank Hiroyuki Miyoshi, Makoto Nakanishi, Yoshikazu Johmura, Yuki Okada, Yoshinori Makino, Takashi Sutani, and Katsuhiko Shirahige for kindly providing materials and technical information, Shiho Takahashi-Kariyazono for technical advice, and all members
-
Mianserin HCl GSK is inhibited by serine phosphorylation
2022-06-08
GSK-3 is inhibited by serine Mianserin HCl at a residue its N-terminus (Ser 9 in GSK-3β and Ser 21 in GSK-3α) [52], [53], [54]. This raised the possibility that the N-terminal tail may function as a pseudo-substrate by mimicking the pre-phosphorylated substrate. The interaction mode of the pseudo-su
-
As part of our discovery
2022-06-08
As part of our discovery efforts searching for small molecule GPR119 agonists, we analyzed active pharmacophores of known agonists from the literature, and found that -methylsulfonylphenyl and substituted 4-hydroxyl piperidine are common fragments. In our initial efforts, we linked these two fragme
-
SGCs tightly ensheath the soma of DRG
2022-06-08
SGCs tightly ensheath the soma of DRG neurons (Costa and Moreira, 2015, Hanani, 2005, Takeda et al., 2009). Intimate associations between SGCs and neurons facilitate bidirectional regulation of SGC function and neuronal excitability. After nerve injury, neuronal hyperexcitability can result in SGC a
-
Reports of hyperlocomotion after administration of
2022-06-08
Reports of hyperlocomotion after administration of ALX-5407 [27] coupled with the lack of hyperlocomotion after administration of SSR504734, a non-sarcosine, long-residence time, competitive inhibitor [19], suggested that the GlyT1 inhibitor chemotype may impact OP. Furthermore, a compound with a co
-
In summary we discovered azaindole substituted hydroxypyrido
2022-06-08
In summary, we discovered 7-azaindole substituted -hydroxypyridone as a potent zinc-binding GLO1 inhibitor (IC=11nM) through lead generation from HTS and structure-based inhibitor design. The X-ray cocrystal structure and the comparison of binding energies with the indole counterpart revealed that b
13555 records 363/904 page Previous Next First page 上5页 361362363364365 下5页 Last page